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Abstract 
Recent brain tumour research has shown abnormalities in 
gene expression as key features for almost all common 
brain tumours investigated. However, there is increasing 
evidence that epigenetic abnormalities are also crucial for 
tumorigenesis. Epigenetic abnormalities are heritable 
alterations affecting gene expression without changing 
the primary DNA sequence. Epigenetic abnormalities in 
meningiomas include abnormal microRNA expression, 
altered DNA methylation and histone and chromatin 
modifications. In this review we identify the role of altered 
expression of microRNA in the development and 
recurrence of meningioma. Based on the review of 
current literature, extensive knowledge of micro-RNA 
expression cannot only determine tumour recurrence and 
prognosis but also opens up new avenues for treatment.  
Keywords: Brain tumor, Meningioma, miro-RNA, 
Epigenetics. 
Introduction  
Meningiomas represent the most frequent intracranial 
tumour entity of non-glial origin with an incidence of 15-
20% among all primary intracranial neoplasms.1,2 Studies 
show that altered micro-RNA (mi-RNA) expression in 
meningiomas may have them functioning as either 
oncogenes or tumour suppressor genes. Mi-RNAs bind 
complementary to one or more messenger RNA (mRNA) 
molecules resulting in post translational gene expression 
silencing and initiate the degradation or the inhibition of 
translation.3 Here the authors review the evidence of the 
effect of altered mi-RNA expression in meningioma.  
Review of Evidence  
Mi-RNAs have a confirmed diagnostic and prognostic role 
in certain types of cancers and have recently become one 
of the most promising areas of neuro-oncology research, 
and may reveal possible targets for drug development 
and therapy. Zhi et al., in 2012 investigated the mi-RNA 
expression profiles in human meningiomas comparing 
levels of 200 mi-RNA from 110 meningioma samples to 
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Figure-1 and 2: MRI T1WI post-contrast axial images show a large left convexity 
meningioma with mass effect and midline shift. Figure 2 is the post-operative MRI 
images showing complete excision and resolution of mass effect.
mi-RNA expression profiles in 35 normal adjacent tissue 
(NAT).4 They identified a molecular profile containing 14 
specific mi-RNAs which distinguished meningiomas from 
NAT samples. Of these 14, they indicated three mi-RNAs 
(miR-190a, miR-29c-3p, miR-219-5p) which may have the 
potential to serve as novel prognostic indicators of 
meningioma. They further reported that high levels of 
miR-190a and low levels of miR-29c-3p and miR-219-5p 
were significantly correlated with elevated recurrence 
rate in meningioma patients.4 We must add here that 
markedly elevated levels of miR-21 have been found in 
glioblastoma. Galani et al., in 2015 reported that atypical 
and malignant meningiomas had higher expression of 
both miR-21 and nestin levels compared to benign 
meningioma.5 A positive correlation between miR-21 and 
nestin mRNA levels was also found.5 
Significantly reduced miR-145 expression was seen in 
atypical and anaplastic tumours as compared to benign 
meningiomas. Moreover, meningioma cells with high 
miR-145 levels had impaired migratory and invasive 
potential in vitro and in vivo. PCR-array studies of miR145-
overexpressing cells suggested that collagen type V alpha 
(COL5A1) expression is down regulated by miR-145 over 
expression. Accordingly, COL5A1 expression was 
significantly upregulated in atypical and anaplastic 
meningiomas.6 Collectively, the data indicates an 
important anti-migratory and anti-proliferative function 
of miR-145 in meningiomas. 
In addition, the use of artificial mi-RNA molecules as 
therapeutic agents is now under intense development. 
Such molecules are modified oligonucleotides that can 
either bind to a specific mi-RNA to enhance or reduce the 
expression of its targets.7 Thus, mi-RNA expression can be 
altered in meningiomas with a prognostic relevance and 
may become a potential therapeutic target in the future. 
Conclusion 
Review of evidence identifies that expression of micro-
RNA is involved in tumour pathogenesis. Multiple studies 
show the changes in micro-RNA expression and their 
effect on prognosis and recurrence. The identification of 
these micro-RNA can help in screening, treatment 
planning prognostication and counselling. It further 
opens up new avenues for research in meningiomas.  
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